The First Case of TEMPI Syndrome in Japan

Intern Med. 2020 Jul 15;59(14):1741-1744. doi: 10.2169/internalmedicine.3547-19. Epub 2020 Apr 16.

Abstract

TEMPI syndrome, a disease entity comprising telangiectasia, erythrocytosis with high erythropoietin, monoclonal gammopathy, perinephric fluid collection, and intrapulmonary shunting, was first described by Sykes et al. in 2011. To our knowledge, only 15 cases have been reported worldwide, none of which were in Japan. We herein report a 47-year-old man who had intractable ascites for 2 and a half years and was referred to our department for a peritoneovenous shunt. In addition to ascites, he had telangiectasia, high erythropoietin, monoclonal gammopathy, and perinephric fluid collection. Thus, this is the first case of TEMPI syndrome in Japan.

Keywords: TEMPI syndrome; erythrocytosis; monoclonal gammopathy; perinephric fluid collection.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antineoplastic Agents / therapeutic use*
  • Bortezomib / therapeutic use*
  • Humans
  • Japan / epidemiology
  • Male
  • Middle Aged
  • Monoclonal Gammopathy of Undetermined Significance / diagnosis
  • Monoclonal Gammopathy of Undetermined Significance / drug therapy*
  • Monoclonal Gammopathy of Undetermined Significance / epidemiology
  • Polycythemia / diagnosis
  • Polycythemia / drug therapy*
  • Polycythemia / epidemiology
  • Telangiectasis / diagnosis
  • Telangiectasis / drug therapy*
  • Telangiectasis / epidemiology
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • daratumumab
  • Bortezomib